Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.
Related to this article
The supplemental new drug application was submitted under the accelerated approval pathway with a request for priority review.
The FDA approved ropeginterferon alfa-2b for the treatment of essential thrombocythemia.
The FDA approved rusfertide for the treatment of patients with polycythemia vera.
The phase 3 INTREPID trial is evaluating sapablursen in phlebotomy-dependent polycythemia vera.
In a phase 1/2 study, the LSD1 inhibitor bomedemstat reduced spleen volume, improved symptoms, and lowered driver mutation burden in patients with advanced myelofibrosis.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Breakthrough Therapy Designation to JBS-003 for Radiation De-Escalation in HPV+ Oropharyngeal Cancer
2
Comprehensive RNA-Based Testing and Selective Next-Generation TKIs Are Reshaping Frontline ROS1+ NSCLC Care
3
Dr Kantarjian on Long-Term Data for Dose-Optimized Ponatinib in CML
4
ASPEN-09-03 Trial Aims to Establish the Role of Evorpacept in Post–T-DXd HER2+ Breast Cancer
5